Rogers
Yahoo Finance • yesterday
Is FDA’s Fast Subcutaneous Lunsumio VELO Approval Reshaping the Investment Case For Roche (SWX:ROG)?
In December 2025, Genentech, part of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory follicular lymphoma after at least two prior... Full story
Yahoo Finance • 3 days ago
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences – – Approval supported by data demonstr... Full story
Yahoo Finance • 3 days ago
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
F. Hoffmann-La Roche Ltd Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported b... Full story
Yahoo Finance • 5 days ago
Does Roche Still Offer Value After a 35.9% Rally and New Oncology Partnerships?
If you are wondering whether Roche Holding is still an attractive opportunity after its recent run, or whether that value is already reflected in the price, this article will walk through what the numbers are really indicating about the st... Full story
Yahoo Finance • 6 days ago
Genentech Announces Agreement With U.S. Government
– Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation – – Influenza portfolio to be made available through TrumpRx.gov and through Genentech’s re... Full story
Yahoo Finance • 9 days ago
Roche (SWX:ROG) Valuation Check After 25% Year-to-Date Share Price Rally
Roche Holding (SWX:ROG) has been quietly rewarding patient shareholders, with the stock gaining about 12% over the past month and roughly 25% year to date, outpacing many large pharma peers. See our latest analysis for Roche Holding. Tha... Full story
Yahoo Finance • 9 days ago
Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities
The new cobas® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems. Laboratories can now perform a greater variety... Full story
Yahoo Finance • 10 days ago
Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for ENHERTU. Roche's PATHWAY HE... Full story
Yahoo Finance • 14 days ago
Roche Secures CE Mark Approval For Automated Mass Spectrometry Reagent Pack
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has obtained CE Mark approval for its mass spectrometry reagent pack designed for antibiotics drug monitoring. This milestone establishes Roche's in-vitro diagnostics (IVD) menu as... Full story
Yahoo Finance • 14 days ago
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
F. Hoffmann-La Roche Ltd With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug monitoring for immunosuppressants an... Full story
Yahoo Finance • 15 days ago
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – – Transformational results support the potential of g... Full story
Yahoo Finance • 15 days ago
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3Transformational results support the potential of girede... Full story
Yahoo Finance • 16 days ago
How New Lunsumio and Columvi Lymphoma Data At Roche (SWX:ROG) Has Changed Its Investment Story
In early December 2025, Roche and Genentech reported new clinical data at the American Society of Hematology meeting showing that Lunsumio and Columvi delivered promising efficacy, durable remissions and manageable safety profiles across m... Full story
Yahoo Finance • 16 days ago
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test will help improve diagnostic accuracy for... Full story
Yahoo Finance • 16 days ago
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone1,2Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a benefit in a complete renal response in... Full story
Yahoo Finance • 17 days ago
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm US cohort of phase III CELESTIMO study1Data from subcutaneous Lunsumio plus Polivy... Full story
Yahoo Finance • 17 days ago
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
– Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study – – Data from subcutaneous Lunsumio plus Po... Full story
Yahoo Finance • 17 days ago
ASUS Republic of Gamers Announces CES 2026 ROG — Dare to Innovate Virtual Launch Event
KEY POINTS Pioneering the Future: ROG marks two decades of boundary-pushing innovation with a showcase of its boldest gaming technologies yetExpanded Innovation: Discover an array of next-gen gaming PCs, laptops, motherboards, and gaming... Full story
Yahoo Finance • 17 days ago
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
F. Hoffmann-La Roche Ltd Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx1 This Columvi combination is available off-the-shelf and could offer a potentially cu... Full story
Yahoo Finance • 20 days ago
Looking at the Narrative for Roche After New Trial Results and Strategic Shifts
Roche Holding’s fair value estimate has edged up to about CHF 312 from roughly CHF 305, supported by a slightly higher long term revenue growth outlook of around 1.51% versus about 1.48% previously. With the discount rate steady near 3.86%... Full story
